ORUKA THERAPEUTICS INC
ORKANASDAQ🏆 #895 by market capUS Equity
$823.44▼ $28.41 (−3.45%)
Simulated price1h—
24h▼ 3.5%
7d—
14d—
30d—
1y—
🏦Market Cap
$6.31B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
127.5x
Expensive
Otter Score
48
Weak
No chart data available for ORKA.
Trading Snapshot
- Day Range
- $820.17 – $839.25
- 52-Week Range
- $12.84 – $105.31
- Volume
- $2.32B
- Avg Volume
- $1.97B
- Shares Outstanding
- 60.3M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $49M
- Last Q Revenue
- $12M
- P/E Ratio
- —
- P/S Ratio
- 127.5x
- EPS (TTM)
- $-2.39
- Dividend Yield
- —
Why Investors Own ORKA
- ✓High-growth profile — revenue up -6.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$49M▼ −5.8% YoY
Gross Margin (TTM)
72.6%▲ +4.1% YoY
Operating Income (TTM)
$8M▼ −5.8% YoY
Free Cash Flow (TTM)
$10M▼ −5.8% YoY
About ORUKA THERAPEUTICS INC
A company profile for ORUKA THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
48/100
Analyst Price Target
ⓘAverage Target
$845.05
▲ +2.6% Upside
High Target$1,057.19
Low Target$652.82
Based on 11 analysts
Latest News & Updates
🚀
Reuters·2h ago
ORUKA THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift ORKA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
ORUKA THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.